Lisata Therapeutics (LSTA)

Develops certepetide, a cyclic peptide being studied with other therapies to help them penetrate solid tumors through the CendR uptake pathway and modify the tumor microenvironment. The pipeline centers on clinical studies in pancreatic and biliary cancers, including investigator-led work in the United States, Australia, New Zealand, Estonia, Latvia, and Lithuania, plus partner-led development in Greater China. The company has no approved products or recurring product sales.

Operates as a single clinical-stage segment, pairing company-sponsored development with investigator trials, territorial licenses, and technology collaborations. Potential economics depend on licensing payments, development and regulatory milestones, royalties, and eventual commercial arrangements; academic sponsors, collaborators, and third parties undertake material clinical and manufacturing work. The portfolio, collaborations, and platform narrative are concentrated on certepetide, while a pending cash tender offer could replace the standalone strategy.